Osimertinib, a third-generation covalent EGFR inhibitor, was shown to induce the apoptosis of the CD34+ leukemia stem and progenitor cells in EGFR-negative AML and CML, but no comparable cell death occurred in CD34− cells. Here, EGFR is linked to acute myeloid leukemia.